{"id":"nordiflex","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, NordiFlex prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively. This mechanism is thought to be responsible for the drug's anti-tumor activity.","oneSentence":"NordiFlex is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:18.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07126288","phase":"PHASE2, PHASE3","title":"Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Kexing Pharmaceutical Co., Ltd.","startDate":"2025-08-31","conditions":"Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone","enrollment":268},{"nctId":"NCT04633057","phase":"PHASE3","title":"A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2021-01-25","conditions":"Pediatric Growth Hormone Deficiency","enrollment":168},{"nctId":"NCT01706783","phase":"PHASE1","title":"A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-10-12","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":35},{"nctId":"NCT01245374","phase":"PHASE4","title":"Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem","enrollment":103},{"nctId":"NCT00936403","phase":"PHASE2","title":"A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-08","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":31},{"nctId":"NCT01500486","phase":"","title":"Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children, Delivery Systems","enrollment":84},{"nctId":"NCT01327924","phase":"","title":"Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-04","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children, Genetic Disorder","enrollment":77}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"CONDITION AGGRAVATED"},{"count":9,"reaction":"CONVULSION"},{"count":7,"reaction":"HEADACHE"},{"count":6,"reaction":"CHEST PAIN"},{"count":6,"reaction":"VOMITING"},{"count":5,"reaction":"NAUSEA"},{"count":5,"reaction":"SCOLIOSIS"},{"count":5,"reaction":"URINARY TRACT INFECTION"},{"count":4,"reaction":"DEHYDRATION"},{"count":4,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NordiFlex","genericName":"NordiFlex","companyName":"TJ Biopharma Co., Ltd.","companyId":"tj-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NordiFlex is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}